ArticleCureus2025
Association of Serum IL-17A and IL-23 Levels With Alopecia Areata: A Cross-Sectional Comparative Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAlopecia areata (AA) is an autoimmune, non-scarring hair loss disorder in which T helper 17 (Th17) cells play a key role. Interleukin-23 (IL-23) promotes the differentiation and expansion of Th17 cells from naïve CD4+ T cells. This study aimed to evaluate the association between serum IL-17A and IL-23 levels and disease severity in patients with AA.
methodsA cross-sectional comparative study was conducted at the Department of Dermatology and Venereology, Bangladesh Medical University, Dhaka, from October 2022 to September 2024. Forty-three AA patients and 43 age- and sex-matched healthy controls were enrolled. Serum IL-17A and IL-23 levels were measured using enzyme-linked immunosorbent assay (ELISA) (Elabscience, USA). Disease severity was assessed using the Severity of Alopecia Tool (SALT) score. Data were analyzed with IBM SPSS Statistics for Windows, Version 26 (released 2018; IBM Corp., Armonk, New York, United States) using chi-square, t-test, Mann-Whitney U, and Spearman's correlation tests, with p<0.05 considered statistically significant.
resultsSerum IL-17A and IL-23 levels were significantly higher in AA patients than controls (IL-17A: 39.4 ± 38.3 vs. 13.7 ± 10.7 pg/mL; IL-23: 48.2 ± 57.0 vs. 15.5 ± 15.5 pg/mL; both p<0.001). IL-17A correlated positively with disease severity (p=0.016), increasing from 21.17 ± 33.26 pg/mL in mild cases (S1, <25% hair loss) to 63.47 ± 50.33 pg/mL in severe cases (S4, 75-99% hair loss). IL-17A levels varied across clinical subtypes (single patch: 20.70 ± 24.46 pg/mL; sisaipho: 53.37 ± 1.33 pg/mL; p=0.044). IL-23 levels remained elevated regardless of disease severity (p=0.118) or clinical subtype (p=0.378). A significant positive correlation existed between IL-17A and IL-23 (p<0.001).
conclusionsElevated IL-17A levels are associated with AA severity and differ across clinical subtypes, suggesting a role in disease progression and phenotype variation. IL-23 is consistently elevated in AA, highlighting its potential as a biomarker for disease activity. These findings provide insight into cytokine dysregulation in AA and may inform future therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.